Outlook Therapeutics (OTLK) Stock Soars After FDA Approval: What Investors Should Know
Outlook Therapeutics shares rise after FDA approval of LYTENAVA, with a significant analyst upgrade and potential for market impact.
Capricor Therapeutics (CAPR): A Cautionary Tale for Biotech Investors Following 67% Drop
Capricor Therapeutics plummets 67% amid FDA concerns, highlighting the high-stakes nature of biotech investments.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Expand Energy's Acquisition of Twin Eagle: A Game Changer for Natural Gas Market
Expand Energy's acquisition of Twin Eagle could reshape North America's natural gas landscape amidst rising geopolitical…
Capricor Therapeutics Faces Critical FDA Review: What’s Next for CAPR Investors?
Capricor Therapeutics navigates a critical FDA review, impacting stock dynamics and future growth potential.
OTLK Stock Soars After FDA Approval: What Investors Need to Know
Outlook Therapeutics' FDA approval for its wet AMD drug could signal a significant opportunity for investors in OTLK sto…
Pfizer's Talzenna-Xtandi Filing: A Potential Game Changer in Prostate Cancer Treatment
Pfizer's Talzenna and Xtandi filing could reshape prostate cancer treatment, signaling a strategic expansion in oncology…
BridgeBio Pharma's NDA for Encaleret: A Significant Milestone for Investors
BridgeBio Pharma's NDA acceptance for encaleret marks a pivotal moment for investors, highlighting potential commerciali…
Hims & Hers Stock Surges After FDA Advisory Panel Backs Peptide Compounding
Hims & Hers stock saw a 13% increase following a favorable FDA panel vote on peptide compounding, raising investor optim…
US Treasury Yield Trends: What Rising Rates Mean for Investors
Understanding the implications of rising US Treasury yields for consumer debt and business costs amidst geopolitical ten…
Mobix Labs Acquires Vision Aerial: A Strategic Move in National Security Tech
Mobix Labs secures Vision Aerial for $15M, enhancing its defense tech portfolio and positioning in drone technology.
Outlook Therapeutics: Anticipating a Critical FDA Decision on Lytenava
Investors are closely watching Outlook Therapeutics as the FDA decision on Lytenava for wet AMD approaches, following tw…